Topoisomerases II are considered to be targets of anthracyclines[11], while TOP2A gene amplification has been linked to anthracycline sensitivity in patients with advanced breast cancer[12,13] or in patients with high-risk primary breast cancer receiving adjuvant chemotherapy[14-16] (reviewed in[17]). This evidence concerns the gene TOP2A and breast carcinoma.